Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $9.33 Average Target Price from Analysts
Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) has received an average recommendation of “Hold” from the nine research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and two have given a buy recommendation to the […]
Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) has received an average recommendation of “Hold” from the nine research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and two have given a buy recommendation to the […]
